The effect of polymorphic alleles carriage of the VKORC1 gene on clinical and laboratory ­parameters in patients with acute coronary syndrome

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Background. The role of the VKORC1 (1639G>A, rs9923231) gene polymorphism in hypersensitivity to warfarin and hypocoagulation is known. It has been proven that polymorphisms in the VKORC1 gene can lead to the progression of atherosclerosis and hypercoagulability, and, therefore, can be factors contributing to the development of acute coronary syndrome.

Aim. To study the effect of polymorphic genotypes carriage of the VKORC1 gene on the clinical and laboratory parameters of patients with acute coronary syndrome.

Material and methods. The pilot observational cross-sectional study involved 77 patients who were under observation in the conditions of the Federal Center for Cardiovascular Surgery in Astrakhan and the vascular center of Kirov City Hospital No. 3 (Astrakhan), from October 2020 to May 2021. Genotyping for CYP2C9, VKORC1, CYP4F2 on a PCR analyzer was performed. For statistical processing, the Hardy–Weinberg and Student criteria; 95% confidence interval were determined using Statistica Trial 13 and IBM SPSS Statistics 26.0. Differences were considered statistically significant at p <0.05.

Results. Significant differences related to the frequency of hemodynamically significant stenosis in homozygous carriers of the GG gene for VKORC1 compared with the group of carriers of the GA genotype — 3 (8.8%) versus 7 (22.5%); p=0.0058. Carriers of the GA and GG genotypes were most often diagnosed with myocardial infarction (Q- and non-Q-forming). Carriers of the AA genotype were more likely to have new or progressive angina pectoris. The level of hyperglycemia and triglyceridemia was the highest in the group of patients with the AA genotype, VKORC1 gene.

Conclusion. Statistically significant differences were established in the clinical and laboratory parameters of patients with acute coronary syndrome, carriers of different genotypes of the VKORC1 gene.

Full Text

Restricted Access

About the authors

Bela I. Kantemirova

Astrakhan State Medical University

Author for correspondence.
ORCID iD: 0000-0003-3278-2556

M.D., D. Sci. (Med.), Prof., Depart. of Pharmacology

Russian Federation, Astrakhan, Russia

Elena N. Chernysheva

Astrakhan State Medical University

ORCID iD: 0000-0001-8884-1178

M.D., D. Sci. (Med.), Assoc. Prof., Head, Depart. of Cardiology

Russian Federation, Astrakhan, Russia

Ekaterina A. Orlova

Astrakhan State Medical University

ORCID iD: 0000-0001-7169-3586

M.D., Cand. Sci. (Med.), Assoc. Prof., Head, Depart. of Pharmacology

Russian Federation, Astrakhan, Russia

Musalitdin A. Abdullaev

Astrakhan State Medical University

ORCID iD: 0000-0001-7374-2660

PhD Student, Depart. of Pharmacology

Russian Federation, Astrakhan, Russia

Olga V. Petrova

Astrakhan State Medical University; Federal Center for Cardiovascular Surgery

ORCID iD: 0000-0003-3544-2266

M.D., Cand. Sci. (Med.), Head, Clinical and Diagnostic Laboratory; Assoc. Prof., Depart. of Cardiovascular Surgery

Russian Federation, Astrakhan, Russia; Astrakhan, Russia

Giorgi A. Rostoshvili

Astrakhan State Medical University

ORCID iD: 0000-0001-7296-4798

Head, Laboratory of the Multifunctional Medical Clinical Center

Russian Federation, Astrakhan, Russia


  1. Petkova NI, Petrova KB, Bliznakova MI, Paskalev DN, Galunska BT. The new face of vitamin K — more than blood clotting factor. Nephrology (Saint-Petersburg). 2018;22(1):29–37. (In Russ.) doi: 10.24884/1561-6274-2018-22-1-29-37.
  2. Mirzaev KB, Fedorinov DS, Ivashchenko DV, Sychev DA. Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population. Rational Pharmacotherapy in Cardiology. 2019;15(3):393–406. (In Russ.) doi: 10.20996/1819-6446-2019-15-3-393-406.
  3. Arslanbekova SM, Goluhova EZ, Sychev DA, Kazakov RE, Kuznetsova EV. Features of the selection of therapeutic doses of warfarin in patients with VKORC1-G3673A gene polymorphism, after heart valve replacement, under polypharmacotherapy. Byulleten NCSSH im AN Bakuleva RAMN. Serdechno-sosudistye zabolevaniya. 2014;15(S3):130. (In Russ.)
  4. Turner RM, de Koning EM, Fontana V, Thompson A, Pirmohamed M. Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: Analysis of a multicentre observational study. BMC Med. 2020;18(1):1–15. doi: 10.1186/s12916-020-01827-z.
  5. Shaw K, Amstutz U, Kim RB, Lesko LJ, Turgeon J, Michaud V, Hwang S, Ito S, Ross C, Carleton BC. Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in Warfarin therapy. Ther Drug Monit. 2015;37(4):428–36. doi: 10.1097/FTD.0000000000000192.
  6. Fedorinov DS, Mirzaev KB, Ivashchenko DV, Temirbulatov II, Sychev DA, Maksimova NR, Chertovskih JV, Popova NV, Tayurskaya KS, Rudykh ZA. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Drug Metab Pers Ther. 2018;33(2):91–98. doi: 10.1515/dmpt-2018-0004.
  7. Dong OM, Wheeler SB, Cruden G, Lee CR, Voora D, Dusetzina SB, Wiltshire T. Cost-effectiveness of multigene pharmacogenetic testing in patients with acute coronary syndrome after percutaneous coronary intervention. Value Health. 2020;23(1):61–73. doi: 10.1016/j.jval.2019.08.002.
  8. Tang W, Shi Q, Ding F, Yu M, Hua J, Wang Y. Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage: A novel systematic review and meta-analysis of 53 studies. Int J Clin Pharmacol Ther. 2017;55(4):304–321. doi: 10.5414/CP202833.
  9. Velizarova M, Hristova J, Svinarov D, Ivanova S, Jovinska S, Abedinov P. The impact of CYP2C9 and VKORC1 genetic polymorphisms in anticoagulant therapy management after cardiac surgery with extracorporeal circulation. Pharmacia. 2021;68(1):269–273. doi: 10.3897/pharmacia.68.e63409.
  10. Kantemirova BI, Orlova EA, Polunina OS, Chernysheva EN, Abdullaev MA, Sychev DA. Pharmacogenetic bases of individual sensitivity and personalized administration of antiplatelet therapy in different ethnic groups. Pharmacy and Pharmacology. 2020;8(6):392–404. (In Russ.) doi: 10.19163/2307-9266-2020-8-6-392-404.
  11. Vesa SC, Trifa AP, Crisan S, Buzoianu AD. VKORC1-1639 G>A Polymorphism in Romanian patients with deep vein thrombosis. Clin Appl Thromb Hemost. 2016;22(8):760–764. doi: 10.1177/1076029615585993.
  12. Wzorek J, Wypasek E, Awsiuk M, Potaczek D, Undas A. Genetic causes of resistance to vitamin K antagonists in Polish patients: a novel p.Ile123Met mutation in VKORC1 gene. Blood Coagul Fibrinolysis. 2018;29(5):429–434. doi: 10.1097/MBC.0000000000000737.
  13. Wang Y, Zhang W, Zhang Y, Yang Y, Sun L, Hu S, Chen J, Zhang C, Zheng Y, Zhen Y, Sun K, Fu C, Yang T, Wang J, Sun J, Wu H, Wayne C, Hui R. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection. Circulation. 2006;113(12):1615–1621. doi: 10.1161/CIRCULATIONAHA.105.580167.
  14. Pankratova YuV, Pigarova EA, Dzeranova LK. Vitamin K-dependent proteins: osteocalcin, matrix gla-protein and extra osseous effects. Obesity and metabolism. 2013;10(2):11–18. (In Russ.) doi: 10.14341/2071-8713-4818.
  15. Suh JW, Baek SH, Park JS, Kang HJ, Chae IH, Choi DJ, Park HJ, Kim PJ, Seung KB, Kim HS. Vitamin K epoxide reductase complex subunit 1 gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation: 2-Center prospective cohort study. Am Heart J. 2009;157(5):908–912. doi: 10.1016/j.ahj.2009.02.001.
  16. Rubanenko AO, Dyachkov VA, Kirichenko NA, Sergeeva TA, Shchukin YuV. Genotype CC VKORC1 is associated with hypercoagulation and decreasing of fibrinolytic activity in patients with permanent atrial fibrillation. Meditsina. 2019;7(2):1–8. (In Russ.) doi: 10.29234/2308-9113-2019-7-2-1-8.
  17. Pang H, Zhang C, Liu F, Gong X, Jin X, Su C. Reduced thrombin activatable fibrinolysis inhibitor and enhanced inflammatory markers in ACS. Minerva Cardioangiol. 2016;41(8):475–482. doi: 10.1016/j.medin.2016.10.008.

Supplementary files

There are no supplementary files to display.

© 2022 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies